Eisai Co., Ltd. (4523) Press Release
LEQEMBI (lecanemab) Subcutaneous Formulation as an Initiation Treatment for Early Alzheimer’s Disease Approved in China
Earlier from Eisai
- CONSOLIDATED FINANCIAL REPORT [IFRS] for the Three-Month Period Ended June 30, 2026
- Revenue of LEQEMBI (Preliminary Basis)
- Historic Step for Alzheimer's Care in Canada: CDA-AMC Recognizes Clinical Value of LEQEMBI® (lecanemab) and Recommends Public Coverage for Early Alzheimer's Disease
- More than 75% of Leqembi®-treated patients remained stable and nearly 7% improved over an average of 17 months of treatment in real-world LEADER study data presented at AAIC® 2026